Clinical trials: Ritonavir, open to volunteers
HIV, HIV Infection
Clinical Trial to Evaluate the Efficacy and Safety of Codivir® in Addition to Standard Antiretroviral Treatment for HIV Infection in Antiretroviral-naïve Participants
The study will begin with a two-week lead-in period (W-2 and W-1), when participants randomized to Codivir® will receive Codivir® 2 mL, 1 subcutaneous injection every day.
- Trial name
- Codivir® (NCT06676410)
- Testing
- ICF, Eligibility Assessment, Demographic data
- Where
- Brazil
- Volunteers
- 40 people
- Sponsor
- Code Pharma
HIV-1-infection, Anxiety Depression
Research on the Psychological Status of Patients With HIV-1 Infection
The goal of this observational study is to investigate the neuropsychological states of People Living With HIV(PLWH), the prevalence of social and psychological stress adaptation overload and poor episodic memory in PLWH.
- Trial name
- NCT07080138
- Testing
- All kinds of INSTI medications, All kinds of conventional medications
- Volunteers
- 500 people
- Sponsor
- Shanxi Bethune Hospital
Post-acute Sequelae of COVID-19, Long COVID
SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID Dysfunction
The purpose of this research study is to test if the combination of three drugs, valacyclovir, celecoxib, and Paxlovid will decrease the symptoms of Long COVID in adults compared to a placebo (this does not contain the…
- Trial name
- SHIELD (NCT07597902)
- Testing
- Valacyclovir, Celecoxib, Paxlovid
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
HER2-positive Advanced Solid Tumor
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
- Trial name
- NCT05150691
- Testing
- DB-1303/BNT323, Pertuzumab Injection, Ritonavir
- Where
- 102 sites in United States, Australia and 4 more
- Volunteers
- 796 people
- Sponsor
- DualityBio Inc.
HIV/AIDS
Simplified Treatment of Anti-retrovirus in China (C-STAR)
To observe the efficacy and safety of simplified therapy regimen for treating with HIV-1 infected patients in Chinese real word.
- Trial name
- NCT03603977
- Testing
- Lpv/r+3TC
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Guangzhou 8th People's Hospital
High-Grade Anal Intraepithelial Neoplasia
Lopinavir/Ritonavir in PLWH With High-Grade AIN
This study is being done to assess the safety of lopinavir/ritonavir in patients with PLWH with AIN. 30 participants will be recruited and can expect to be on active study for approximately 3 months and long term follow up for 40…
- Trial name
- NCT05334004
- Testing
- Lopinavir / Ritonavir
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Wisconsin, Madison
COVID-19
A Real World Study of Paxlovid for the Treatment of Hospitalized Patients Confirmed With COVID-19
The study was designed to analyze the efficacy and safety of Paxlovid for the treatment of COVID-19.
- Trial name
- NCT05387369
- Testing
- Paxlovid
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Huashan Hospital
HIV Infections, HBV Coinfection
Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses
The main objective of this study is to evaluate at 96 weeks the safety with respect to hepatitis B control of 2 treatment reduction strategies for patients with previously controlled HIV-HBV co-infection on continuous triple…
- Trial name
- BI-LIGHT (NCT06338826)
- Testing
- TDF - 245mg or TAF -25mg associated to 3TC - 300mg or FTC - 200mg and a NNRTI or PI/r or INSTI, Dual therapy with 3TC in combination with DTG or ritonavir-boosted Darunavir (rDVR)
- Volunteers
- 140 people
- Sponsor
- ANRS, Emerging Infectious Diseases
COVID-19
EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease
The purpose of this clinical trial is to learn about the safety, pharmacokinetics (pharmacokinetics helps us understand how the drug is changed and eliminated from your body after you take it), and efficacy (how well a study…
- Trial name
- NCT05261139
- Testing
- nirmatrelvir, ritonavir
- Where
- 73 sites in United States, Bulgaria and 5 more
- Volunteers
- 160 people
- Sponsor
- Pfizer
COVID-19, Long Haul
Covid-19 Long Haul Preventative and Health Promotion Care Clinical Trial Acceleration Program.
Investigators are conducting a study on alternative treatments for patients who have received an current or previous positive COVID-19 diagnosis with mild-serve symptoms or undiagnosable condition after testing positive for…
- Trial name
- NCT06441955
- Testing
- Ritonavir-Boosted Nirmatrelvir (Paxlovid), Physiological Evaluation, Moderna COVID-19 Vaccine
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Well- Konnect Healthcare Services and Research Firm
COVID-19, SARS-CoV-2
Extended Remdesivir Infusion Combined With Nirmatrelvir/Ritonavir for Persistent SARS-CoV-2 Infection in Immunocompromised Patients
To evaluate the safety and efficacy of extended remdesivir infusion, targeting on immunocompromised individuals who had positive SARS-CoV-2 PCR despite an oral antiviral agent prescription.
- Conditions
- COVID-19, SARS-CoV-2, Immunocompromised
- Trial name
- SARS-CoV-2 (NCT06610643)
- Testing
- combination therapy, SOC
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- National Taiwan University Hospital
Intracerebral Hemorrhage, Atrial Fibrillation
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF).
- Trial name
- ASPIRE (NCT03907046)
- Testing
- Apixaban, Aspirin
- Where
- 187 sites in United States
- Volunteers
- 700 people
- Sponsor
- Yale University
COVID-19, SARS-CoV-2 Infection, RSV
Clinical Outcomes and Pharmacotherapy Effectiveness in the VA Health Care System (COPE-VA)
The purpose of this study is to comprehensively describe the temporal and geographic utilization of COVID-19 therapies used for mild to moderate disease during different periods of SARS-CoV-2 variant circulation as well as to…
- Conditions
- COVID-19, SARS-CoV-2 Infection, RSV, Influenza
- Trial name
- COPE-VA (NCT06160128)
- Where
- United States
- Volunteers
- 400,000 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Covid19
AGILE (Early Phase Platform Trial for COVID-19)
The AGILE platform master protocol allows incorporation of a range of identified and yet-to-be-identified candidates as potential treatments for adults with COVID-19 into the trial.
- Trial name
- AGILE (NCT04746183)
- Testing
- CST-2: EIDD-2801, Nitazoxanide, VIR-7832
- Where
- 7 sites in South Africa, United Kingdom
- Volunteers
- 600 people
- Sponsor
- University of Liverpool
Respiratory Tract Diseases, Influenza (Pandemic)
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of hospitalised…
- Conditions
- Respiratory Tract Diseases, Influenza (Pandemic), Influenza, Community Acquired Pneumonia
- Trial name
- REMAP-CAP (NCT02735707)
- Testing
- Ceftriaxone + Macrolide, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam + Macrolide
- Where
- 408 sites in United States, Australia and 27 more
- Volunteers
- 20,000 people
- Sponsor
- UMC Utrecht
HIV Infection
An Adaptive Platform Trial for Evaluation of Novel Treatment Regimens in Children and Adolescents With HIV in Africa
The goal of the CHAPAS-5 clinical trial is to find out how well different HIV treatments work in children and young people (from 4 weeks up to under 15 years old) living with HIV, including those starting treatment for the first…
- Trial name
- CHAPAS-5 (NCT07792096)
- Testing
- Dolutegravir (DTG), Abacavir (ABC), Lamivudine (3TC)
- Volunteers
- 800 people
- Sponsor
- University College, London
Human Papilloma Virus (HPV), High-risk Human Papillomavirus Infection
A Study of the Preliminary Efficacy of DARE-HPV to Treat High-risk Persistent Human Papillomavirus (hrHPV)
The goal of this clinical study is to learn if DARE-HPV can treat persistent high-risk human papillomavirus (hrHPV). The primary outcome will be if the genital infection clears following treatment in 30, 60 or 90 days.
- Trial name
- NCT07601074
- Testing
- Lopinavir / ritonavir
- Where
- 11 sites in United States
- Volunteers
- 118 people
- Sponsor
- Daré Bioscience, Inc.
Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose…
- Conditions
- Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension
- Trial name
- POPS or POP02 (NCT04278404)
- Testing
- The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
- Where
- 52 sites in United States, Canada
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Duke University
SARS CoV-2 Post-Acute Sequelae
Antiviral Strategies in the Prevention of Long-term Cardiovascular Outcomes Following COVID-19: The paxloviD/Remdesivir Effectiveness For the prEvention of loNg coviD Clinical Trial
The DEFEND trial will be the world's first clinical trial to study the effectiveness of Paxlovid or Veklury in the prevention of cardiovascular post-acute sequelae of SARS-CoV-2 among hospitalized adults.
- Trial name
- DEFEND (NCT06792214)
- Testing
- Nirmatrelvir/ritonavir, Remdesivir
- Where
- 4 sites in Canada
- Volunteers
- 118 people
- Sponsor
- Mount Sinai Hospital, Canada
HIV, Drug Resistance
B-free Multistage Trial
The primary objective of the study is to evaluate the efficacy of a booster-free regimen including DOR/DTG/3TC among HIV-suppressed PLWH with previous virological failure.
- Conditions
- HIV, Drug Resistance, Drug Drug Interaction
- Trial name
- B-free (NCT06037564)
- Testing
- DOR/DTG/3TC
- Where
- 8 sites in Switzerland
- Volunteers
- 210 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern